TY - JOUR
T1 - Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device
AU - Mobilise-D consortium
AU - Kirk, Cameron
AU - Küderle, Arne
AU - Micó-Amigo, M. Encarna
AU - Bonci, Tecla
AU - Paraschiv-Ionescu, Anisoara
AU - Ullrich, Martin
AU - Soltani, Abolfazl
AU - Gazit, Eran
AU - Salis, Francesca
AU - Alcock, Lisa
AU - Aminian, Kamiar
AU - Becker, Clemens
AU - Bertuletti, Stefano
AU - Brown, Philip
AU - Buckley, Ellen
AU - Cantu, Alma
AU - Carsin, Anne Elie
AU - Caruso, Marco
AU - Caulfield, Brian
AU - Cereatti, Andrea
AU - Chiari, Lorenzo
AU - D’Ascanio, Ilaria
AU - Garcia-Aymerich, Judith
AU - Hansen, Clint
AU - Hausdorff, Jeffrey M.
AU - Hiden, Hugo
AU - Hume, Emily
AU - Keogh, Alison
AU - Kluge, Felix
AU - Koch, Sarah
AU - Maetzler, Walter
AU - Megaritis, Dimitrios
AU - Mueller, Arne
AU - Niessen, Martijn
AU - Palmerini, Luca
AU - Schwickert, Lars
AU - Scott, Kirsty
AU - Sharrack, Basil
AU - Sillén, Henrik
AU - Singleton, David
AU - Vereijken, Beatrix
AU - Vogiatzis, Ioannis
AU - Yarnall, Alison J.
AU - Rochester, Lynn
AU - Mazzà, Claudia
AU - Eskofier, Bjoern M.
AU - Del Din, Silvia
N1 - Publisher Copyright:
© 2024, The Author(s).
PY - 2024/12
Y1 - 2024/12
N2 - This study aimed to validate a wearable device’s walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson’s Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and − 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application. Trial registration: ISRCTN – 12246987.
AB - This study aimed to validate a wearable device’s walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson’s Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and − 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application. Trial registration: ISRCTN – 12246987.
UR - http://www.scopus.com/inward/record.url?scp=85182823472&partnerID=8YFLogxK
U2 - 10.1038/s41598-024-51766-5
DO - 10.1038/s41598-024-51766-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38243008
AN - SCOPUS:85182823472
SN - 2045-2322
VL - 14
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 1754
ER -